Business Update & Financial Outlook
Advancing and augmenting our deep pipeline
Q Oncology
Highlighted important data at ASCO:
KEYNOTE-671 for neoadjuvant and
adjuvant for the treatment of non-
small cell lung cancer
KEYTRUDA in combination with
V9401, our Individualized
Neoantigen Therapy (INT) for the
treatment of adjuvant melanoma
MK-28702, our TROP-2 ADC, for
the treatment of non-small cell
lung cancer
Q Vaccines and Infectious Disease
Announced positive topline results
for V116, our pneumococcal
conjugate vaccine candidate
specifically designed for adults
General Medicine
Cardiometabolic
Completed FDA submission of
sotatercept in PAH based on the
Phase 3 STELLAR trial
Presented Phase 2a data at EASL for
efinopegdutide, our GLP-1/
glucagon receptor co-agonist, in
NAFLD
Immunology
Completed acquisition of
Prometheus Biosciences
1. In collaboration with Moderna 2. In collaboration with Kelun
MERCK
7View entire presentation